AATAC Trial: Ablation Vs. Amiodarone for Persistent Atrial Fibrillation in CHF
| Name of the Trial |
| AATAC |
| Title of the Trial |
| Ablation vs. amiodarone for Atrial Fibrillation in patients with CHF and an implanted device |
| Design |
| Multicenter, parallel-group, open-label, randomized controlled trial |
| Year of Publication |
| 2016 |
| Objective |
| To assess if AF ablation is superior to amiodarone in patients HFrEF (LVEF ≤40%) and persistent AF. |
| Number of Patients (N) |
| 203 |
| Inclusion Criteria |
| Patients with: persistent AF, dual-chamber ICD or CRT-D, NYHA II to III, and LVEF <40% within the past 6 months |
| Duration of Follow up |
| 24 months |
| Comparison groups |
| AF ablation (n=203) vs amiodarone (n=203) |
| Primary Outcomes |
| Atrial arrhythmia-free survival 70% vs 34% (p<0.001) |
| Key Secondary Outcomes |
| Unplanned hospitalization 31% vs 57% RR 0.55, 95% CI 0.39-0.76, p<0.001 Death 8% vs 18% RR 0.44, 95% CI -0.20 to 0.96, p=0.037 LVEF (change from baseline) 8.1 vs 4.0 p=0.02 |
| Conclusion |
| In patients with NYHA II-III HFrEF and persistent AF, AF ablation was associated with a 36% absolute increase in AF-free survival. |
| Citation, article link |
| Di Biase et al. Circulation. 2016. 133(17):1637-1634. |